Hrk supply Rosuvastatin calcium Raw materials powder

CAS:147098-20-2

MF:C22H30CaFN3O6S

MW:523.63

EINECS:627-028-1

Specification: 99% min Rosuvastatin calcium powder

Sample:Rosuvastatin calcium powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Store at -20°C

Shelf Life: 2 Years

Test Method: HPLC

Rosuvastatin calcium powder of Usage and Synthesis.

Primary hypercholesterolemia: Common dose of rosuvastatin calcium (10mg) can significantly reduce LDLC levels in patients with primary hypercholesterolemia, with greater efficiency than atorvastatin calcium (10mg), and TC and TG levels decreased more at the end of the experiment. In addition, 5mg of rosuvastatin calcium has a better effect on reducing LDLC level than 10mg of atorvastatin calcium in the same 8-week course, and the difference is statistically significant. This suggests that the lipid lowering effect of rosuvastatin calcium is better than atorvastatin calcium. Our trial is also consistent with the results of previous studies evaluating the efficacy of statins (STELLAR, MERCURY) : Rosuvastatin calcium is more potent than other statins (atorvastatin, simvastatin, and pravastatin) in reducing LDLC, enabling more patients to achieve the recommended treatment goal.

Uses of Rosuvastatin calcium.

Pharmacological action of Rosuvastatin calcium.

Rosuvastatin is a selective HMG-CoA reductase inhibitor. HMG-CoA reductase inhibitors are rate-limiting enzymes that convert 3-hydroxy-3-methylglutaryl-CoA to valerate, A precursor of cholesterol. The main site of action of rosuvastatin is the liver - a targeted organ for lowering cholesterol. Rosuvastatin increased the number of receptors on the surface of liver LDL cells, promoted the absorption and catabolism of LDL, inhibited the liver synthesis of VLDL, and thus reduced the total number of VLDL and LDL particles. For homozygous and heterozygous patients with familial hypercholesterolemia, non-familial hypercholesterolemia, and mixed dyslipidemia, rosuvastatin can reduce the levels of total cholesterol, LDL-C, ApoB, and non-HDL-C. Rosuvastatin also decreased TG and increased HDL-C levels. In patients with simple hypertriglyceridemia, rosuvastatin can reduce total cholesterol, LDL-C, VLDL-C, ApoB, non-HDL-C, TG levels, and increase HDL-C levels. Preclinical data based on general safety pharmacology, repeated dose toxicity, potential genotoxicity, and carcinogenicity studies do not show specific toxicity to humans. In studies of rats before and after birth, the reproductive toxicity of rosuvastatin was evident, reducing litter size, weight, and birth rate. These reproductive toxicity phenomena were observed when female rats were given toxic doses that made their systemic exposure several times higher than the therapeutic exposure level.

Product Methods of Bulk Rosuvastatin calcium powder.